NextCure (NXTC) AI Stock Analysis

• Market Cap: $45.43M
• Dividend Yield: N/A
• Average Volume (3M): 37.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: 3.78%
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.22
• Shares Outstanding: 3,505,621
• 10 Day Avg. Volume: 95,061
• 30 Day Avg. Volume: 37,578
• PEG Ratio: 0.03
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: -0.37
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.29
• 1Y Price Target: $17.67
• Price Target Upside: 36.34% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $13.50 ▲(4.17% Upside)

The score is held down primarily by weak financial performance (no revenue, continued losses, and heavy cash burn with elevated funding/dilution risk). This is partly offset by strong technical uptrend and supportive recent financing actions that extend runway, while valuation remains constrained by unprofitability and lack of dividend support.

Positive Factors

Strong Equity Position

A strong equity position with low debt enhances financial stability, providing a solid foundation for future growth and investment in R&D.

Strategic Partnerships

Strategic partnerships provide essential funding and expertise, facilitating R&D progress and potential revenue streams from milestone payments and royalties.

Pipeline Advancement

Advancing clinical trials like LNCB74 demonstrates NextCure's commitment to innovation and addressing unmet medical needs, potentially enhancing market position.

Negative Factors

Lack of Revenue

The absence of revenue generation poses a challenge to financial sustainability, requiring reliance on external funding and partnerships to continue operations.

Cash Burn

Ongoing cash burn without revenue generation stresses financial resources, necessitating additional funding to maintain operations and support R&D efforts.

Declining Assets

Decreasing assets and equity indicate potential liquidity issues, which could limit NextCure's ability to invest in future growth and innovation.

NextCure Business Overview & Revenue Model

Company Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

How the Company Makes Money

NextCure primarily generates revenue through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve joint development agreements, where NextCure provides its proprietary technology and expertise in exchange for research funding, milestone payments, and potential royalties on future product sales. Additionally, the company may receive revenue from government grants supporting specific research initiatives. However, as a clinical-stage company, NextCure has not yet achieved commercial sales of its products, which means its revenue streams are largely dependent on these collaborative and developmental agreements.

NextCure Financial Statement Overview

Summary

NextCure's financials reflect a typical early-stage biotech company with no revenue generation and a focus on research and development. The income statement shows operational challenges with negative EBIT and net income. The balance sheet is stable due to a strong equity position and low debt, but declining assets pose sustainability concerns. Cash flow analysis indicates significant cash burn and reliance on cash reserves, highlighting the need for additional funding or revenue generation.

Income Statement

NextCure's income statement shows a lack of revenue generation with consistent negative EBIT and net income, reflecting operational challenges. The absence of revenue growth and negative margins indicate significant financial strain, typical of early-stage biotech companies focused on R&D without marketable products.

Balance Sheet

The balance sheet reflects a strong equity position and low debt levels, with a favorable equity ratio. However, declining total assets and equity over the years pose concerns about sustainability. The company's reliance on cash reserves for funding operations highlights potential liquidity risks if revenue streams don't materialize.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows with no signs of improvement, suggesting ongoing cash burn. The company's cash reserves have decreased substantially, although the ability to generate positive investing cash flow offers some relief. This trend indicates a need for external financing or strategic shifts to ensure long-term viability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	22.38M
Gross Profit	0.00	-2.87M	0.00	0.00	0.00	-24.18M
EBITDA	-57.50M	-54.34M	-63.95M	-71.78M	-66.59M	-37.81M
Net Income	-58.01M	-55.65M	-62.72M	-74.73M	-69.39M	-36.60M
Balance Sheet
Total Assets	39.61M	80.86M	128.04M	184.16M	242.39M	306.64M
Cash, Cash Equivalents and Short-Term Investments	29.11M	68.62M	108.30M	159.91M	219.59M	283.45M
Total Debt	4.41M	5.95M	6.61M	7.12M	0.00	3.47M
Total Liabilities	15.97M	15.39M	13.62M	16.63M	9.00M	12.92M
Stockholders Equity	23.65M	65.47M	114.42M	167.53M	233.39M	293.72M
Cash Flow
Free Cash Flow	-48.91M	-41.28M	-53.79M	-56.00M	-59.60M	-52.09M
Operating Cash Flow	-48.94M	-40.80M	-52.97M	-53.89M	-57.24M	-44.95M
Investing Cash Flow	26.51M	55.31M	39.27M	67.98M	36.60M	43.52M
Financing Cash Flow	2.06M	144.00K	154.00K	200.00K	-3.27M	-1.42M

NextCure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXTC, the sentiment is Positive. The current price of 12.96 is above the 20-day moving average (MA) of 12.77, above the 50-day MA of 11.75, and above the 200-day MA of 7.29, indicating a bullish trend. The MACD of 0.51 indicates Positive momentum. The RSI at 52.69 is Neutral, neither overbought nor oversold. The STOCH value of 37.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NXTC.

NextCure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NXTC	54 Neutral	$45.43M	-0.53	-116.91%	―	―	3.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NERV	50 Neutral	$186.51M	-2.34	―	―	―	-323.61%
ETHZ	45 Neutral	$102.86M	-0.08	-371.02%	―	―	―
MTVA	44 Neutral	$12.51M	-0.22	-168.18%	―	―	71.57%
APM	42 Neutral	$8.63M	-2.99	-9.02%	―	―	-1979.68%
ATON	41 Neutral	$6.99M	-0.01	―	―	―	―

NextCure Corporate Events

NextCure Launches At-The-Market Stock Offering Program

On December 19, 2025, NextCure, Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $14.5 million of its common stock from time to time through the agent on Nasdaq or other permitted markets at prevailing or negotiated prices, with the agent earning a 3% commission on gross proceeds. The company plans to use any net proceeds for general corporate purposes and working capital, including funding preclinical studies, clinical trials and advancement of its product candidates, a move that could bolster its R&D pipeline and operational flexibility, while customary indemnification and legal opinions have been put in place to support the offering structure.

The most recent analyst rating on (NXTC) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.

NextCure Raises $21.5M in Private Placement

On November 12, 2025, NextCure, Inc. entered into a securities purchase agreement with institutional and accredited investors for a private placement of common stock and pre-funded warrants, raising approximately $21.5 million. The offering closed on November 14, 2025, with H.C. Wainwright & Co. as the sole placement agent. The proceeds will extend NextCure’s cash runway into the first half of 2027, beyond the planned 2026 proof of concept data readouts for its ADC programs, SIM0505 and LNCB74. This strategic financial move is expected to bolster NextCure’s operations and industry positioning as it advances its clinical programs.

The most recent analyst rating on (NXTC) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.